Gregorio Alexander Nolasco’s research while affiliated with Hospital Sant Joan de Déu and other places

What is this page?


This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.

Publications (1)


Targeted therapy with galantamine in a pediatric patient with 15q13.3 deletion syndrome
  • Article

July 2021

·

48 Reads

·

3 Citations

American Journal of Medical Genetics Part A

·

Gregorio Alexander Nolasco

·

María Díez‐Juan

·

[...]

·

Carmen Fons

Citations (1)


... Similarly, there are reports of individuals with 15q13.3 deletion syndrome associated with schizophrenia, intellectual disability, epilepsy, aggression and autism spectrum disorders (ASD) where CHRNA7, the gene encoding the α7-nicotinic acetylcholine receptor subunit, is deleted (Casas-Alba et al., 2021;Cubells et al., 2011). The acetylcholinesterase inhibitor, galantamine, was observed to reduce aggression in one adult with psychosis and intellectual disability (Cubells et al., 2011) and improve fluid reasoning, working memory, and processing speed in one youth with ASD (Casas-Alba et al., 2021). ...

Reference:

A genetics-guided approach to the clinical management of schizophrenia
Targeted therapy with galantamine in a pediatric patient with 15q13.3 deletion syndrome
  • Citing Article
  • July 2021

American Journal of Medical Genetics Part A